First- and second-line therapy in patients with ECD-C and ECD-noC
| . | ECD-noC (n = 65) . | ECD-C (n = 39) . | Total (N = 104) . | P value . |
|---|---|---|---|---|
| First-line treatment received, n (%) | 57 (88) | 37 (95) | 94 (90) | .31 |
| Targeted therapy | 23 (40) | 21 (57) | 44 (47) | .14 |
| BRAF inhibitor | 14 (25) | 17 (46) | 31 (33) | |
| MEK inhibitor | 8 (14) | 5 (14) | 13 (14) | |
| Tyrosine kinase inhibitor | 1 (2) | 0 (0) | 1 (1) | |
| Conventional therapy | 34 (60) | 17 (46) | 51 (54) | .21 |
| IFN-α or PEG–IFN-α | 7 (12) | 8 (22) | 15 (16) | |
| Cytokine-directed therapy | 3 (5) | 2 (5) | 4 (4) | |
| Cytotoxic chemotherapy | 15 (26) | 8 (22) | 23 (25) | |
| Corticosteroids | 8 (14) | 1 (3) | 9 (10) | |
| Other | 4 (7) | 0 (0) | 4 (7) | |
| Second-line treatment received, n (%) | 21 (37) | 17 (46) | 38 (40) | .40 |
| Targeted therapy | 9 (43) | 10 (59) | 19 (50) | .52 |
| BRAF inhibitor | 4 (19) | 9 (53) | 13 (34) | |
| MEK inhibitor | 5 (24) | 2 (12) | 7 (18) | |
| Conventional therapy | 13 (62) | 8 (47) | 21 (55) | .51 |
| IFN-α or PEG–IFN-α | 4 (19) | 1 (6) | 5 (13) | |
| Cytokine-directed therapy | 2 (10) | 4 (24) | 6 (16) | |
| Cytotoxic chemotherapy | 7 (33) | 2 (12) | 9 (24) | |
| Corticosteroids | 1 (5) | 0 (0) | 1 (3) | |
| Other | 0 (0) | 1 (6) | 1 (3) |
| . | ECD-noC (n = 65) . | ECD-C (n = 39) . | Total (N = 104) . | P value . |
|---|---|---|---|---|
| First-line treatment received, n (%) | 57 (88) | 37 (95) | 94 (90) | .31 |
| Targeted therapy | 23 (40) | 21 (57) | 44 (47) | .14 |
| BRAF inhibitor | 14 (25) | 17 (46) | 31 (33) | |
| MEK inhibitor | 8 (14) | 5 (14) | 13 (14) | |
| Tyrosine kinase inhibitor | 1 (2) | 0 (0) | 1 (1) | |
| Conventional therapy | 34 (60) | 17 (46) | 51 (54) | .21 |
| IFN-α or PEG–IFN-α | 7 (12) | 8 (22) | 15 (16) | |
| Cytokine-directed therapy | 3 (5) | 2 (5) | 4 (4) | |
| Cytotoxic chemotherapy | 15 (26) | 8 (22) | 23 (25) | |
| Corticosteroids | 8 (14) | 1 (3) | 9 (10) | |
| Other | 4 (7) | 0 (0) | 4 (7) | |
| Second-line treatment received, n (%) | 21 (37) | 17 (46) | 38 (40) | .40 |
| Targeted therapy | 9 (43) | 10 (59) | 19 (50) | .52 |
| BRAF inhibitor | 4 (19) | 9 (53) | 13 (34) | |
| MEK inhibitor | 5 (24) | 2 (12) | 7 (18) | |
| Conventional therapy | 13 (62) | 8 (47) | 21 (55) | .51 |
| IFN-α or PEG–IFN-α | 4 (19) | 1 (6) | 5 (13) | |
| Cytokine-directed therapy | 2 (10) | 4 (24) | 6 (16) | |
| Cytotoxic chemotherapy | 7 (33) | 2 (12) | 9 (24) | |
| Corticosteroids | 1 (5) | 0 (0) | 1 (3) | |
| Other | 0 (0) | 1 (6) | 1 (3) |
Percentages are calculated using the number of individuals who received treatment as the denominator. BRAF inhibitors (vemurafenib, dabrafenib), MEK inhibitors (cobimetinib, trametinib), tyrosine kinase inhibitor (imatinib), cytokine-directed therapy (anakinra, infliximab), cytotoxic chemotherapy (cladribine, methotrexate, cyclophosphamide, vinorelbine, vinblastine, hydroxyurea, IA Melphalan), corticosteroid (prednisone), and other (tamoxifen, pembrolizumab, radiation, surgery). Patients may have received >1 treatment type.
IFN-α, interferon alfa; PEG-IFN-α, pegylated interferon alpha.